<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We treated five patients with intractable <z:e sem="disease" ids="C0029077" disease_type="Disease or Syndrome" abbrv="">sympathetic ophthalmia</z:e> and six patients with severe <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease by high-dose, short-term <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>We used a total dose ranging from 306 mg to 4.2 g and a duration of therapy no longer than 36 weeks and in most cases less than 24 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>After termination of therapy <z:hpo ids='HP_0000001'>all</z:hpo> 11 patients had a sustained remission of their <z:e sem="disease" ids="C0015397" disease_type="Disease or Syndrome" abbrv="">eye disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Unless subretinal neovascularisation was present, <z:hpo ids='HP_0000001'>all</z:hpo> had a final visual acuity of 20/50 or better </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Malignancy</z:e> has not developed in any of our cases, with a follow-up ranging from 6 months to 12 years (mean, 4.5 years) </plain></SENT>
<SENT sid="5" pm="."><plain>Although 30- and 40-year follow-ups and larger numbers of patients may be necessary fully to realise the risks of <z:chebi fb="5" ids="28830">chlorambucil</z:chebi>, we believe that our high-dose, short-term regimen (<z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease: average duration, 23 weeks; average total dose 2.2 g; <z:e sem="disease" ids="C0029077" disease_type="Disease or Syndrome" abbrv="">sympathetic ophthalmia</z:e>: average duration, 11 weeks; total average dose, 0.9 g) may be safer than previously reported <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> regimens of one to two years or longer </plain></SENT>
<SENT sid="6" pm="."><plain>In addition we fulfilled our aim of discontinuing <z:hpo ids='HP_0000001'>all</z:hpo> concomitant systemic <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> within a relatively short time (usually six to eight weeks) </plain></SENT>
</text></document>